ARQ: Record sales and margins support upgraded 2026 EBITDA guidance and PAC-led PFAS growth

What happened

Arq reported third-quarter revenue of $38.2 million, up 9% year over year, net income of $2.5 million, and adjusted EBITDA of $8.8 million, up 71%. It raised its 2026 adjusted EBITDA guidance to $19–20 million and said PAC for PFAS testing is targeting sales in 2027.

Confirmed

Global impact / market context

Higher reported earnings and raised guidance suggest Arq expects stronger operating results in 2026. If achieved, that could increase cash available for operations or investment. The planned PAC sales add a possible growth source, but the article gives no expected sales amount or profit contribution.

Analyst inference

The update combines improved current-quarter results with a higher forecast for 2026, while the PAC opportunity remains aimed at 2027. That timing means investors are weighing near-term earnings expectations against a later potential revenue stream whose scale is not stated.

Analyst inference

What to watch

1. Arq’s next results can show whether revenue growth and adjusted EBITDA gains continue, and whether actual performance supports the raised 2026 guidance. Analyst inference
2. The company says PAC for PFAS testing is targeting 2027 sales; the article does not confirm sales have begun or specify expected revenue. Confirmed
3. Look for further detail on PAC’s expected sales and costs, since those figures would help assess whether this planned offering can add meaningful profit. Analyst inference

Evidence

• Original source link unavailable